A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
The goal of this clinical research study is to find the highest tolerable dose of CYC140 that can be given to patients with advanced leukemia or myelodysplastic syndrome (MDS). The safety of CYC140 will also be studied. This is the first study using CYC140 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: CYC140
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Cyclacel Ltd.
IRB Review and Approval Date: 10/24/2018
Recruitment Status: Open
Projected Accrual: 50
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: